Clinical Trials Logo

Clinical Trial Summary

This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01786096
Study type Interventional
Source Seattle Genetics, Inc.
Contact
Status Completed
Phase Phase 1
Start date February 2013
Completion date May 30, 2017

See also
  Status Clinical Trial Phase
Completed NCT01943682 - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Phase 1
Completed NCT01093586 - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Recruiting NCT05020392 - Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma Phase 3
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Terminated NCT03864419 - Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda Phase 1
Terminated NCT02700022 - A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas Phase 1
Completed NCT00849147 - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Phase 2
Completed NCT00822432 - Coproporphyrine Isomers and Methotrexate Elimination N/A
Recruiting NCT00180882 - LMBA02 Protocol for Patients With a Burkitt Lymphoma Phase 3
Recruiting NCT06060782 - Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine Phase 1
Active, not recruiting NCT02996773 - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Phase 1
Recruiting NCT05565417 - Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Phase 1/Phase 2
Not yet recruiting NCT03298828 - CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma Phase 1
Completed NCT01290120 - Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma Phase 2
Active, not recruiting NCT00719888 - Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting NCT04425421 - Recommendations for the Treatment of Children With Burkitt's Lymphoma
Completed NCT00001337 - Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT05518383 - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Phase 4
Terminated NCT01028716 - Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2